Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26985308 | 0.71 | NPC1 (0.34) | L3MBTL1 | |
| SCHEMBL30746647 | 0.68 | TSHR (0.37) | KDM4EL3MBTL1KMT2AMAPT | |
| SCHEMBL26985174 | 0.68 | TSHR (0.37) | KDM4EL3MBTL1KMT2AMAPT | |
| SCHEMBL11445528 | 0.66 | KDM4E (0.42) | KDM4EL3MBTL1KMT2ACYP2D6MAPT | |
| SCHEMBL13663805 | 0.65 | L3MBTL1 (0.45) | KDM4EL3MBTL1KMT2ACYP2D6MAPT | |
| SCHEMBL8241575 | 0.65 | L3MBTL1 (0.45) | KDM4EL3MBTL1KMT2ACYP2D6MAPT | |
| SCHEMBL24128156 | 0.65 | KDM4E (0.37) | KDM4EL3MBTL1CYP2D6MAPT | |
| SCHEMBL11446277 | 0.64 | KDM4E (0.40) | KDM4EL3MBTL1KMT2ACYP2D6MAPT | |
| SCHEMBL26017934 | 0.63 | L3MBTL1 (0.43) | KDM4EL3MBTL1KMT2ACYP2D6MAPT | |
| SCHEMBL950779 | 0.62 | KDM4E (0.44) | KDM4EL3MBTL1KMT2ACYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | KDM4E 546/4885L3MBTL1 2931/4885KMT2A 1556/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | KDM4E 940/4885L3MBTL1 3858/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.